Wordt geladen...
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these...
Bewaard in:
| Gepubliceerd in: | Br J Haematol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7687130/ https://ncbi.nlm.nih.gov/pubmed/32220069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16616 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|